ArticleNature cancer2026
PRET is a few-shot system for pan-cancer recognition without example training.
Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Pathological examination stands as the cornerstone in cancer diagnosis, impacting millions worldwide annually. With the shortage of pathologists globally, artificial intelligence (AI) has emerged rapidly to automate the diagnostics process. However, conventional AI models require substantial labeled data for each disease, posing huge challenges in scalability and practicality. Therefore, we introduce PRET (pan-cancer recognition without examples training), a few-shot system to achieve flexible, scalable, and effective cancer recognition across diverse organs, hospitals and tasks without training. Evaluated on 23 international benchmarks comprising 4,484 whole-slide images, our method outperforms existing approaches across 20 tasks, achieving over 97% area under the curve on 15 benchmarks with a maximum improvement of 36.76%. Notably, PRET delivers clinical-grade diagnostic performance in lymph node metastasis detection using only eight slide examples, outperforming 11 pathologists. By offering a flexible and cost-effective solution for pan-cancer recognition, PRET paves the way for accessible and equitable AI-based pathology systems, particularly benefiting minority populations and underserved regions.
Indexed as
Identifiers
41933183What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.